Loading...
01/10 23:51
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call shows mixed results: slight revenue decline due to currency impact, but improved margins and net income. Product sales varied, with strong growth in Home Solutions but declines in U.S. Dental Equipment. The Q&A highlighted concerns about currency impacts and tariffs, but management was vague on specifics. Share repurchases and restructuring savings are positive, but guidance is only moderate. Overall, the sentiment is neutral as the positives and negatives seem balanced.
Global Sales $3.2 billion, down 0.1% year-over-year due to a 1.5% decrease from foreign currency exchange and a 1.2% growth from acquisitions.
GAAP Operating Margin 5.53%, an improvement of 81 basis points year-over-year.
Non-GAAP Operating Margin 7.25%, a 14 basis point improvement year-over-year, driven by lower operating expenses from restructuring.
GAAP Net Income $110 million or $0.88 per diluted share, compared to $93 million or $0.72 per diluted share last year.
Non-GAAP Net Income $143 million or $1.15 per diluted share, compared to $143 million or $1.10 per diluted share last year.
Adjusted EBITDA $259 million, compared to $255 million in the first quarter of the previous year.
U.S. Dental Merchandise Sales Growth Grew low single digits, excluding PPE, with product pricing in line with last year.
U.S. Dental Equipment Sales Growth Declined 8.9% due to a deferral of approximately $20 million in sales from Q4 2023 to Q1 2024, making year-over-year comparisons difficult.
U.S. Medical Distribution Sales Growth Grew 4.7% after excluding PPE and COVID test kits.
Home Solutions Business Sales Growth Total sales growth of 23%, including 9% internal growth.
International Dental Merchandise Sales Growth Constant currency sales grew 1.1%.
International Dental Equipment Sales Growth Constant currency sales grew 4.3%, driven by strong growth in Canada and Central Europe.
Global Specialty Products Group Sales Growth Constant currency sales growth of 4.3%, benefiting from acquisition growth of 4%.
Restructuring Expenses $25 million or $0.14 per diluted share, mainly related to severance benefits.
Operating Cash Flow Generated $37 million in the first quarter, typically lower cash flow quarter.
Share Repurchases Approximately 2.3 million shares repurchased at an average price of $71.58 per share, totaling $161 million.
Authorized Stock Repurchases Approximately $718 million available for future stock repurchases.
New Product Launches: Several new products and solutions were launched in Specialty Products and Technology businesses, including a new dental imaging subscription plan.
Home Solutions Platform Expansion: Acquisition of Excentis, a distributor of continuous glucose monitors, broadening the Home Solutions platform.
Dental Equipment Innovations: New products showcased at the IDS International Dental Show, including 3D printers and intraoral scanners.
Market Expansion: Sales growth in international dental merchandise was strong in Canada, Central Europe, and Brazil, despite some softness in France.
U.S. Dental Market Stability: U.S. Dental merchandise sales grew low single digits, with consistent demand for traditional and digital equipment.
Global E-commerce Platform Launch: The global e-commerce platform in the U.K. and Ireland is fully operational, with a phased launch in North America expected in Q3.
Operational Efficiency: Restructuring initiatives implemented to right-size expenses in distribution businesses and consolidate manufacturing facilities.
Cost Savings: Expected annual run rate savings of $75 million to $100 million by the end of 2025.
Bold Plus One Strategy: The strategic plan has been refreshed for 2025-2027, focusing on operational efficiency, customer experience, and digital solutions.
Business Unit Structure: Established two main business units: Global Distribution and Value Added Service Group, and Global Technology Group.
Foreign Exchange Impact: Sales growth was significantly impacted by the strong U.S. Dollar, with a headwind of about 1.5% from foreign exchange in the first quarter.
Tariff Risks: Current tariffs may impact financial results, but the company is working closely with suppliers and customers to mitigate these effects. They have diversified sourcing to lower tariff countries.
Supply Chain Challenges: A supply chain issue with the EDGE ProLaser product affected sales in the Endodontics business, although this issue has been resolved.
Market Stability: While the U.S. implant market showed slight weakness, the overall dental and medical markets are stable, with some growth in practice build-outs.
Economic Factors: The company noted that consumer sentiment and macroeconomic conditions could change rapidly, impacting business performance.
Competitive Pressures: The company is facing competitive pressures in the dental equipment market, particularly with pricing and market share.
Bold plus One Strategic Plan: The plan has been refreshed for 2025 to 2027, focusing on growing the distribution business, enhancing customer experience, and developing digital solutions.
New Business Units: Established two main business units: Global Distribution and Value Added Service Group, and Global Technology Group.
High Growth, High Margin Businesses: Expect these businesses to contribute over half of total operating income by the end of the strategic planning cycle in 2027.
Home Solutions Platform: Acquired Excentis, a distributor of continuous glucose monitors, to broaden the Home Solutions platform.
Global E-commerce Platform: The UK and Ireland platform is operational, with a phased launch in North America expected in Q3 2025.
2025 Non-GAAP EPS Guidance: Expected to be in the range of $4.80 to $4.94, more heavily weighted to the second half of the year.
2025 Adjusted EBITDA Guidance: Expected to grow in the mid-single digits compared to 2024 adjusted EBITDA of $1.1 billion.
2025 Total Sales Growth Guidance: Expected to be 2% to 4% over 2024.
Effective Tax Rate: Estimated non-GAAP effective tax rate of 25%.
Restructuring Costs: Not able to provide GAAP guidance due to uncertainty in estimating restructuring costs.
Share Repurchase: Approximately 2,300,000 shares of common stock were repurchased during the first quarter at an average price of $71.58 per share, totaling $161,000,000. At quarter end, there was approximately $718,000,000 authorized and available for future stock repurchases.
The earnings call reflects a positive sentiment with strong financial performance, strategic growth initiatives, and stable market conditions. Despite some uncertainties in guidance, the company shows solid growth in key segments, optimistic future earnings, and market share gains. The involvement of KKR and the stabilization of margins further support a positive outlook. The Q&A session highlighted management's confidence in continued growth and strategic advancements, although some specifics were withheld. Overall, the positive aspects outweigh the uncertainties, suggesting a positive stock price movement in the near term.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
